Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
qn-302 save search
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K
|
Health Technology
|
| O: 3.2%
H: 0.0%
C: -0.28%
qn-302 association positive cancer research meeting therapeutics
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
Published: 2023-11-07 (Crawled : 14:00) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K
|
Health Technology
|
| O: 2.86%
H: 4.17%
C: 0.38%
qn-302 tumors treatment trial therapeutics
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023
Published: 2023-09-27 (Crawled : 14:30) - biospace.com/
QLGN | $0.315 6.67% -8.16% 14K
|
Health Technology
|
| O: 0.96%
H: 0.0%
C: -1.9%
qn-302 cancer pancreatic therapeutics
Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors
Published: 2023-08-17 (Crawled : 12:00) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K
|
Health Technology
|
| O: -0.94%
H: 0.0%
C: -1.83%
qn-302 tumors treatment therapeutics
Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
Published: 2023-08-01 (Crawled : 12:00) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K
|
Health Technology
|
| O: 10.62%
H: 0.8%
C: -9.6%
qn-302 fda tumors treatment clearance trial therapeutics
Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL
Published: 2023-04-18 (Crawled : 13:00) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K
|
Health Technology
|
| O: 0.5%
H: 3.16%
C: -5.95%
qn-302 association cancer research meeting therapeutics
Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office
Published: 2023-03-21 (Crawled : 13:00) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K
|
Health Technology
|
| O: 22.45%
H: 14.17%
C: -5.0%
qn-302 patent granted
Data on Potential Biomarker for Qualigen Therapeutics’ Lead Program QN-302 Published in Peer-Reviewed Journal Molecules
Published: 2023-03-08 (Crawled : 13:20) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K
|
Health Technology
|
| O: 1.59%
H: 3.13%
C: -8.59%
qn-302 program biomarker potential
Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302
Published: 2023-01-24 (Crawled : 14:20) - biospace.com/
QLGN | $0.315 6.67% -8.16% 14K
|
Health Technology
|
| O: 3.13%
H: 0.0%
C: -3.03%
qn-302 therapeutics
Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer
Published: 2023-01-10 (Crawled : 16:00) - biospace.com/
QLGN | $0.315 6.67% -8.16% 14K
|
Health Technology
|
| O: 20.47%
H: 3.92%
C: -12.42%
qn-302 designation drug therapeutics food cancer pancreatic
Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors
Published: 2022-12-07 (Crawled : 14:20) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K
|
Health Technology
|
| O: 0.0%
H: 0.62%
C: -6.21%
qn-302 treatment drug therapeutics food tumors
Qualigen Therapeutics Presents Data on QN-302 at AACR’s Pancreatic Cancer Meeting
Published: 2022-09-14 (Crawled : 22:00) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K
|
Health Technology
|
| O: 0.0%
H: 3.85%
C: -0.85%
qn-302 meeting therapeutics cancer pancreatic
Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board
Published: 2022-08-18 (Crawled : 13:20) - globenewswire.com
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: 0.24%
H: 0.26%
C: -1.64%
LLY | News | $745.69 1.96% 0.04% 1.4M
|
Health Technology
|
| O: -0.02%
H: 0.7%
C: -0.01%
BMO | $93.82 0.89% 0.0% 1
|
Finance
|
| O: -0.15%
H: 1.03%
C: 0.68%
QLGN | $0.315 6.67% -8.16% 14K
|
Health Technology
|
| O: 0.19%
H: 0.94%
C: -1.18%
qn-302 meeting therapeutics
Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302
Published: 2022-07-06 (Crawled : 16:00) - biospace.com/
QLGN | $0.315 6.67% -8.16% 14K
|
Health Technology
|
| O: 4.65%
H: 0.19%
C: -5.48%
qn-302 partnership sciences therapeutics
Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials
Published: 2022-06-07 (Crawled : 13:20) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K
|
Health Technology
|
| O: -1.54%
H: 4.48%
C: -1.1%
qn-302 trials program therapeutics trial
Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference
Published: 2022-04-12 (Crawled : 14:20) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K
|
Health Technology
|
| O: -4.43%
H: 160.94%
C: 59.11%
qn-302 research conference therapeutics cancer
Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302
Published: 2022-03-30 (Crawled : 13:20) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K
|
Health Technology
|
| O: -1.07%
H: 4.62%
C: 1.31%
qn-302 research preclinical contract therapeutics pre-clinical
Data from Qualigen Therapeutics’ Lead Program QN-302 Accepted as Three Poster Presentations at AACR 2022 Conference
Published: 2022-02-15 (Crawled : 14:30) - globenewswire.com
QLGN | $0.315 6.67% -8.16% 14K
|
Health Technology
|
| O: 0.41%
H: 4.51%
C: 0.75%
qn-302 program conference therapeutics presentation
Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302
Published: 2022-02-01 (Crawled : 14:30) - biospace.com/
QLGN | $0.315 6.67% -8.16% 14K
|
Health Technology
|
| O: -0.33%
H: 9.61%
C: 1.53%
qn-302 program therapeutics
The Worldwide Digital Transformation Industry is Expected to Reach $1,302 Billion by 2027 at a CAGR of 20.8% from 2021
Published: 2021-07-13 (Crawled : 23:00) - prnewswire.com
SAP | News | $188.01 5.52% 0.31% 1.5M
|
Technology Services
|
| O: 0.39%
H: 0.3%
C: 0.01%
ORCL | News | $115.09 0.49% 0.1% 4.4M
|
Technology Services
|
| O: 0.01%
H: 1.83%
C: 1.38%
HPE | $16.83 0.36% 1.5K
|
Electronic Technology
|
| O: 0.94%
H: 2.38%
C: 0.86%
ACN | News S | $316.83 -0.19% -0.11% 1.6M
|
Technology Services
|
| O: 0.13%
H: 0.79%
C: 0.43%
MSFT | News 4 | $407.57 1.65% 1.54% 11M
|
Technology Services
|
| O: 0.49%
H: 0.47%
C: 0.06%
EQIX | $761.9 0.95% 0.96% 28K
|
Finance
|
| O: -0.09%
H: 1.51%
C: 1.16%
CTSH | $67.77 -0.63% -0.66% 2.1M
|
Technology Services
|
| O: 1.31%
H: 0.53%
C: -0.53%
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
HKIT | $1.33 30.39% 27.14% 39K
|
Technology Services
VRT 4 | $79.17 4.08% 19.36% 6.6M
|
Electronic Technology
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
EAST | $1.0835 16.17% 15.21% 100
|
Commercial Services
BOF | $1.17 6.36% 14.73% 15K
|
TSLA | News | $144.68 1.85% 9.01% 93M
|
Consumer Durables
BNED | $0.2064 2.64% 8.96% 1.4M
|
Retail Trade
HLTH | $0.15 6.38% 7.84% 21K
|
LRN 4 | $58.2 0.17% 7.56% 950K
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.